论文部分内容阅读
目的探讨基线高敏C反应蛋白(hsC-RP)对无高血压病史的糖尿病人群新发心脑血管事件的影响。方法采用前瞻性队列研究方法,以参加健康体检的101510名开滦集团职工中FPG≥7.0mmol/L或已确诊为糖尿病,正在使用降糖药物的2973例糖尿病患者作为观察队列,平均随访(47.26±5.38)个月。结果基线hsC-RP水平增高,心脑血管事件发生率、死亡率、全因死亡率增高(P<0.05)。Cox风险模型表明,hsC-RP>3.0mg/L者发生心脑血管事件、心脑血管死亡、全因死亡的风险分别是hsC-RP≤3.0mg/L者的1.63倍(95%CI:1.03～2.57)、2.62倍(95%CI:1.12～6.12)和1.73倍(95%CI:1.06～2.84)。结论基线hsC-RP>3.0mg/L增加无高血压病史的糖尿病人群新发心脑血管事件的风险。
Objective To investigate the effect of baseline high-sensitivity C-reactive protein (hsC-RP) on new-onset cardiovascular and cerebrovascular events in diabetics with no history of hypertension. Methods A prospective cohort study was conducted in 29150 diabetics with FPG≥7.0mmol / L or diabetes diagnosed among 101,510 Kailuan Group workers who participated in the health checkup. The average follow-up was 47.26 ± 5.38) months. Results The baseline hsC-RP level increased, cardiovascular and cerebrovascular events, mortality, all-cause mortality increased (P <0.05). Cox risk models showed that patients with hsC-RP> 3.0 mg / L had a 1.63-fold (95% CI: 1.03) risk of cardiovascular and cardiovascular death and all-cause mortality, respectively ~ 2.57), 2.62-fold (95% CI: 1.12-6.12) and 1.73-fold (95% CI: 1.06-2.84). Conclusions Baseline hsC-RP> 3.0 mg / L increases the risk of new cardiovascular and cerebrovascular events in diabetic subjects without a history of hypertension.